
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company with a strong focus on oncology and innovative treatments through its synthetic Bicycle technology, demonstrating promising early Phase 1 results for the product candidate BT8009 that suggest a favorable probability of success. The company's advanced clinical assets, BT8009 and BT5528, have exhibited encouraging efficacy and acceptable safety profiles in treating urothelial and ovarian cancers, indicating potential market viability. Additionally, the robust enrollment rates in clinical trials for the Duravelo-2 study reflect positive momentum, underscoring the company's ability to attract interest and support for its innovative therapies in high unmet medical need areas.
Bears say
Bicycle Therapeutics PLC faces significant challenges that contribute to a negative outlook for its stock. Key financial concerns include the potential 0% success rate for its product candidate, BT8009, which would substantially diminish the company's platform value, and recent lackluster Phase 1 clinical trial data for its oncology indications. Additionally, higher-than-anticipated SG&A expenses and the inherent risks associated with the development of novel therapeutics further complicate Bicycle's financial stability and may lead to diminished investor confidence, even if short-term expectations are met.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares